Do not use Wegovy (semaglutide) if: You or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Whether Southend Pharmacy and Boothwyn Pharmacy operate under the 503A patient-specific compounding framework or the 503B outsourcing-facility framework wasn't stated in the materials reviewed, and it's relevant given the active FDA rulemaking on 503B bulk compounding of these exact medications discussed earlier in this article
Preclinical research suggests that GLP-1 receptor activation may strengthen tight junctions between intestinal epithelial cells, reducing the translocation of bacterial products (like lipopolysaccharide) that trigger systemic immune activation
With consistent use, many experienced notable improvements, including the ability to walk longer distances comfortably
#HealthEconomics #VBHC #EuropeanHealthcare #HealthcareData To view or add a comment, sign in In response to the post by Michael Albert MD about GLP-1 access and obesity care infrastructure, I had to chime in